Company & Sponsor Intelligence

Pfizer

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials36

Recruiting1

Completed21

Countries4

Therapeutic footprint

adhdalzheimersanxietydepressionepilepsymigraine_headacheneuromuscularother_neurologyother_psychiatrypain_neuropathyparkinsonsschizophreniastroke

Indexed studies

NCT03546400Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
adhd · PHASE4

NCT00843115Observational Study Of Donepezil In Routine Clinical Practice
alzheimers · TERMINATED

NCT00735267A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
anxiety · United StatesPHASE3

NCT00939783An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT00809354Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
other_neurology · United StatesPHASE3

NCT01456936Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
other_psychiatry · United StatesPHASE4

NCT01371734A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
depression · United StatesPHASE3

NCT00467766Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease
alzheimers · United StatesNA

NCT00409175Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
alzheimers · United StatesPHASE2, PHASE3

NCT00930059A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT02006290Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
parkinsons · United StatesPHASE1

NCT01028911A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE1

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →